Guggenheim Has Lowered Expectations for Rapport Therapeutics (NASDAQ:RAPP) Stock Price

Rapport Therapeutics (NASDAQ:RAPP) had its price target lowered by investment analysts at Guggenheim from $70.00 to $66.00 in a report issued on Thursday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. Guggenheim‘s price objective suggests a potential upside of 170.05% from the stock’s current price.

Other equities research analysts also recently issued research reports about the company. William Blair started coverage on Rapport Therapeutics in a report on Tuesday, July 28th. They issued an “outperform” rating on the stock. JonesTrading lifted their price objective on shares of Rapport Therapeutics from $50.00 to $82.00 and gave the stock a “buy” rating in a research report on Wednesday, October 21st. BTIG Research increased their price target on shares of Rapport Therapeutics from $75.00 to $89.00 and gave the company a “buy” rating in a research note on Tuesday, October 20th. TD Cowen reiterated a “buy” rating on shares of Rapport Therapeutics in a research report on Tuesday, October 20th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Rapport Therapeutics in a research report on Thursday, October 15th. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Rapport Therapeutics has an average rating of “Moderate Buy” and an average price target of $64.50.

Rapport Therapeutics Stock Up 3.0%

Shares of Rapport Therapeutics stock traded up $0.72 during mid-day trading on Thursday, hitting $24.44. The stock had a trading volume of 866,406 shares, compared to its average volume of 1,444,809. Rapport Therapeutics has a 12-month low of $22.06 and a 12-month high of $52.93. The firm has a market cap of $1.17 billion, a P/E ratio of -7.71 and a beta of 1.40. The firm has a 50-day moving average of $34.16 and a two-hundred day moving average of $35.53.

Rapport Therapeutics (NASDAQ:RAPP) last posted its earnings results on Wednesday, November 4th. The company reported ($0.84) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.20) by $0.36. Sell-side analysts expect that Rapport Therapeutics will post -3.90 earnings per share for the current year.

Insider Activity at Rapport Therapeutics

In other news, Director John Maraganore purchased 9,411 shares of the business’s stock in a transaction dated Thursday, October 22nd. The stock was acquired at an average price of $26.45 per share, with a total value of $248,920.95. Following the purchase, the director directly owned 9,411 shares of the company’s stock, valued at $248,920.95. This represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, COO Cheryl Gault sold 10,000 shares of Rapport Therapeutics stock in a transaction dated Wednesday, September 30th. The stock was sold at an average price of $33.19, for a total transaction of $331,900.00. Following the transaction, the chief operating officer owned 139,914 shares of the company’s stock, valued at approximately $4,643,745.66. The trade was a 6.67% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders acquired 1,031,174 shares of company stock valued at $22,023,898 and sold 97,976 shares valued at $4,391,729. 12.48% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Rapport Therapeutics

Large investors have recently bought and sold shares of the stock. AlphaCentric Advisors LLC increased its position in Rapport Therapeutics by 6.8% during the first quarter. AlphaCentric Advisors LLC now owns 6,438 shares of the company’s stock worth $201,000 after buying an additional 408 shares in the last quarter. Sterling Capital Management LLC lifted its position in shares of Rapport Therapeutics by 597.9% in the third quarter. Sterling Capital Management LLC now owns 984 shares of the company’s stock valued at $33,000 after acquiring an additional 843 shares in the last quarter. KBC Group NV purchased a new stake in shares of Rapport Therapeutics in the first quarter valued at $30,000. State of Wyoming purchased a new stake in shares of Rapport Therapeutics in the second quarter valued at $65,000. Finally, Swiss National Bank boosted its stake in shares of Rapport Therapeutics by 3.5% during the first quarter. Swiss National Bank now owns 56,500 shares of the company’s stock valued at $1,768,000 after acquiring an additional 1,900 shares during the last quarter.

Rapport Therapeutics News Summary

Here are the key news stories impacting Rapport Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its EPS estimates across 2026–2030, projecting smaller losses than before. For example, its FY2027 estimate improved to a loss of $4.29 per share from $6.80, and its FY2026 estimate to a loss of $3.18 from $4.51. The firm reiterated its Buy rating and $66 price target. The more favorable projections may support sentiment toward RAPP. HC Wainwright earnings estimate updates
• Negative Sentiment: UBS lowered its price target to $64 from $71, while maintaining a Buy rating. The reduction tempers the positive analyst outlook, although the revised target remains well above the share price cited in the report. UBS price-target update

About Rapport Therapeutics

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for central nervous system disorders. The company’s approach is designed to selectively target receptor-associated proteins that regulate synaptic receptors, with the goal of improving therapeutic selectivity and reducing the side effects associated with broader-acting neurological medicines.

Rapport’s lead product candidate, RAP-219, is an orally administered small molecule being developed for neurological conditions, including focal epilepsy.